China Resources Jiangzhong PharmaceuticalLtd (600750) Stock Overview
Engages in the manufacture of pharmaceutical products in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
600750 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
China Resources Jiangzhong Pharmaceutical Co.,Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥25.30 |
| 52 Week High | CN¥25.89 |
| 52 Week Low | CN¥21.05 |
| Beta | 0.21 |
| 1 Month Change | 1.36% |
| 3 Month Change | 3.48% |
| 1 Year Change | 12.00% |
| 3 Year Change | 36.83% |
| 5 Year Change | 135.13% |
| Change since IPO | 3,064.38% |
Recent News & Updates
Recent updates
Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Price Is Right But Growth Is Lacking
Jan 24
Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750) Analysts Just Slashed This Year's Revenue Estimates By 11%
Sep 12Lacklustre Performance Is Driving Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E
Jul 20A Look At The Fair Value Of Jiang Zhong Pharmaceutical Co.,Ltd (SHSE:600750)
May 22Why Investors Shouldn't Be Surprised By Jiang Zhong Pharmaceutical Co.,Ltd's (SHSE:600750) Low P/E
Apr 15Shareholder Returns
| 600750 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 0.8% | -0.3% | -0.5% |
| 1Y | 12.0% | 10.5% | 23.6% |
Return vs Industry: 600750 exceeded the CN Pharmaceuticals industry which returned 10.5% over the past year.
Return vs Market: 600750 underperformed the CN Market which returned 23.6% over the past year.
Price Volatility
| 600750 volatility | |
|---|---|
| 600750 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 4.3% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in CN Market | 10.1% |
| 10% least volatile stocks in CN Market | 3.2% |
Stable Share Price: 600750 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600750's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4,182 | Wenbin Xiao | www.jzjt.com |
China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsules, bezoar and snake gallbladder Fritillaria liquid, and compound gold melon seed. It also provides health consumer and other products, such as nourishing, rehabilitation nutrition, gastrointestinal health, and liver health products.
China Resources Jiangzhong Pharmaceutical Co.,Ltd Fundamentals Summary
| 600750 fundamental statistics | |
|---|---|
| Market cap | CN¥15.93b |
| Earnings (TTM) | CN¥824.08m |
| Revenue (TTM) | CN¥4.24b |
Is 600750 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600750 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.24b |
| Cost of Revenue | CN¥1.55b |
| Gross Profit | CN¥2.69b |
| Other Expenses | CN¥1.86b |
| Earnings | CN¥824.08m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Mar 20, 2026
| Earnings per share (EPS) | 1.31 |
| Gross Margin | 63.39% |
| Net Profit Margin | 19.44% |
| Debt/Equity Ratio | 0% |
How did 600750 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/16 07:51 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
China Resources Jiangzhong Pharmaceutical Co.,Ltd is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shiyu Chen | China International Capital Corporation Limited |
| Han Wei Yu | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Wentao Li | Citic Securities Co., Ltd. |